EXPH5

Across TCGA pan-cancer cohorts, EXPH5 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated EXPH5 data layer compared with 23 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher EXPH5 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated EXPH5 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

HNSC, LUAD, and PDAC are the cancer types where EXPH5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Quartile	II,III,IV	0.911	0.642	.012	23	view →
LUAD	OS	Median	II,III,IV	1.000	0.862	.004	18	view →
PDAC	OS	Median	II,III,IV	0.570	0.365	.007	16	view →
UCEC	OS	Median	All	1.000	0.929	.018	6	view →
CCRCC	DFS	Median	All	0.999	0.830	.030	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

EXPH5–HNSC (OS)

Open the HNSC breakdown →